- Home
- MTUS vs TRVI Comparison
MTUS vs TRVI Comparison
Compare MTUS & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTUS
- TRVI
- Stock Information
- Founded
- MTUS 1899
- TRVI 2011
- Country
- MTUS United States
- TRVI United States
- Employees
- MTUS N/A
- TRVI N/A
- Industry
- MTUS
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- MTUS
- TRVI Health Care
- Exchange
- MTUS NYSE
- TRVI Nasdaq
- Market Cap
- MTUS 699.0M
- TRVI 675.8M
- IPO Year
- MTUS N/A
- TRVI 2019
- Fundamental
- Price
- MTUS $13.39
- TRVI $6.50
- Analyst Decision
- MTUS
- TRVI Strong Buy
- Analyst Count
- MTUS 0
- TRVI 8
- Target Price
- MTUS N/A
- TRVI $17.56
- AVG Volume (30 Days)
- MTUS 357.4K
- TRVI 1.3M
- Earning Date
- MTUS 05-08-2025
- TRVI 05-08-2025
- Dividend Yield
- MTUS N/A
- TRVI N/A
- EPS Growth
- MTUS N/A
- TRVI N/A
- EPS
- MTUS N/A
- TRVI N/A
- Revenue
- MTUS $1,042,900,000.00
- TRVI N/A
- Revenue This Year
- MTUS $9.13
- TRVI N/A
- Revenue Next Year
- MTUS $10.82
- TRVI N/A
- P/E Ratio
- MTUS N/A
- TRVI N/A
- Revenue Growth
- MTUS N/A
- TRVI N/A
- 52 Week Low
- MTUS $10.78
- TRVI $2.30
- 52 Week High
- MTUS $24.31
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- MTUS 53.90
- TRVI 53.10
- Support Level
- MTUS $11.00
- TRVI $6.12
- Resistance Level
- MTUS $13.60
- TRVI $7.17
- Average True Range (ATR)
- MTUS 0.53
- TRVI 0.46
- MACD
- MTUS 0.10
- TRVI -0.07
- Stochastic Oscillator
- MTUS 90.53
- TRVI 34.22
About MTUS METALLUS INC
Metallus Inc is an America-based manufacturer of alloy steel, as well as carbon and micro-alloy steel. The portfolio of the company includes special bar quality steel, seamless mechanical tubes, and value-add solutions, such as precision steel components. The company also supplies machining and thermal treatment services and manages raw material recycling programs that work as a feeder system for its melt operations. The company's products and services are used in the following sectors: oil and gas; automotive; industrial equipment; mining; construction; rail; aerospace and defense; heavy truck; agriculture; and power generation. Geographically, the company mainly serves customers in the United States.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.